VivoSeq
Oncology

Leptomeningeal Metastasis

31

Pipeline Programs↗

17

Active Trials↗

20

Companies Involved↗

Leptomeningeal Metastasis is a moderately active landscape with 31 programs across 20 companies. The most active players are Coherus Oncology, Inc., Y-mAbs Therapeutics, Tracon Pharmaceuticals Inc.. 5 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

67/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Coherus Oncology, Inc.

1 program

Phase 1Y

Y-mAbs Therapeutics

1 program

Phase 2T

Tracon Pharmaceuticals Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2E

Eagle Vision Pharmaceutical Corp.

1 program

Phase 2BeiGene logo

BeiGene

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

74%

Small molecule

26 of 35 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody823%Radiopharmaceutical13%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 100% of 35 pipeline programs.

Analysis

Trial Status

28

clinical trials

Recruiting14 · 50%
Unknown status5 · 18%
Completed4 · 14%
Not yet recruiting2 · 7%
Withdrawn2 · 7%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

28 trials

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
Recruiting·FFudan University·Phase 4·NCT06230055·37 enrolled
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07263425·26 enrolled
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
Recruiting·GGuangzhou Medical University·N/A·NCT06304441·100 enrolled
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Recruiting·HHenan Cancer Hospital·N/A·NCT06643000·60 enrolled
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05184816·35 enrolled
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Recruiting·GGuangzhou Medical University·Phase 2·NCT06296745·36 enrolled
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis
Recruiting·JJiangsu Province Nanjing Brain Hospital·Phase 2·NCT06332287·25 enrolled
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06543992·22 enrolled
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Recruiting·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT05805631·23 enrolled
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Recruiting·JJiangsu Province Nanjing Brain Hospital·Phase 2·NCT06339242·30 enrolled
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Recruiting·GGuangzhou Medical University·Phase 1/2·NCT06809530·34 enrolled
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Recruiting·GGuangzhou Medical University·Phase 1/2·NCT06762080·36 enrolled
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Recruiting·GGuangzhou Medical University·Phase 1/2·NCT06809517·34 enrolled
A Prospective Single Arm Phase II Exploratory Study on the Combination of Whole Brain Radiotherapy, Thiotepa Intrathecal Injection and Systemic Treatment of Primary Diseases in the Treatment of Solid Tumor Leptomeningeal Metastasis
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06376292·58 enrolled
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Active, not recruiting·GGuangzhou Medical University·Phase 1/2·NCT06462222·45 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)